In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
In the latest session, Beam Therapeutics Inc (NASDAQ: BEAM) closed at $16.44 down -1.20% from its previous closing price of $16.64. In other words, the price has decreased by -$1.20 from its previous closing price. On the day, 2.05 million shares were traded. BEAM stock price reached its highest trading level at $16.97 during the session, while it also had its lowest trading level at $16.38.
Ratios:
For a deeper understanding of Beam Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.75 and its Current Ratio is at 6.75. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.14.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 30 ’25 when FMR LLC sold 48,374 shares for $20.50 per share. The transaction valued at 991,667 led to the insider holds 2,073,665 shares of the business.
Simon Amy sold 876 shares of BEAM for $17,625 on Jul 03 ’25. The Chief Medical Officer now owns 64,864 shares after completing the transaction at $20.12 per share. On Jul 01 ’25, another insider, Simon Amy, who serves as the Chief Medical Officer of the company, sold 374 shares for $16.94 each. As a result, the insider received 6,336 and left with 65,740 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BEAM now has a Market Capitalization of 1683340928 and an Enterprise Value of 620135168. For the stock, the TTM Price-to-Sale (P/S) ratio is 27.59 while its Price-to-Book (P/B) ratio in mrq is 1.58. Its current Enterprise Value per Revenue stands at 10.289 whereas that against EBITDA is -1.463.
Stock Price History:
The Beta on a monthly basis for BEAM is 2.14, which has changed by -0.37466717 over the last 52 weeks, in comparison to a change of 0.14460516 over the same period for the S&P500. Over the past 52 weeks, BEAM has reached a high of $35.25, while it has fallen to a 52-week low of $13.52. The 50-Day Moving Average of the stock is -11.92%, while the 200-Day Moving Average is calculated to be -26.05%.
Shares Statistics:
For the past three months, BEAM has traded an average of 2.27M shares per day and 2773250 over the past ten days. A total of 100.76M shares are outstanding, with a floating share count of 91.26M. Insiders hold about 9.79% of the company’s shares, while institutions hold 101.30% stake in the company. Shares short for BEAM as of 1753920000 were 24615341 with a Short Ratio of 10.84, compared to 1751241600 on 24076439. Therefore, it implies a Short% of Shares Outstanding of 24615341 and a Short% of Float of 27.35.
Earnings Estimates
The stock of Beam Therapeutics Inc (BEAM) is currently being evaluated by 10.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$1.06, with high estimates of -$0.79 and low estimates of -$1.24.
Analysts are recommending an EPS of between -$3.78 and -$4.92 for the fiscal current year, implying an average EPS of -$4.3. EPS for the following year is -$4.39, with 13.0 analysts recommending between -$3.01 and -$5.73.
Revenue Estimates
A total of 11 analysts believe the company’s revenue will be $13.57M this quarter.It ranges from a high estimate of $25M to a low estimate of $8M. As of the current estimate, Beam Therapeutics Inc’s year-ago sales were $14.27MFor the next quarter, 11 analysts are estimating revenue of $13.84M. There is a high estimate of $25M for the next quarter, whereas the lowest estimate is $8M.
A total of 13 analysts have provided revenue estimates for BEAM’s current fiscal year. The highest revenue estimate was $65.9M, while the lowest revenue estimate was $31.9M, resulting in an average revenue estimate of $46.84M. In the same quarter a year ago, actual revenue was $63.52MBased on 13 analysts’ estimates, the company’s revenue will be $46.83M in the next fiscal year. The high estimate is $110M and the low estimate is $80k.
